NCT05745961

Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 6 (estimated)
• Sponsor: Imperial College London · Academic / Other
• Sex: All
• Age: 25 Years – 75 Years
• Healthy volunteers: —

Summary

The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand \[11C\]PBR28) in the lungs of patients living with PAH relative to age matched controls. If so, TSPO PET may be a useful technique to non-invasively monitor response to therapy. To do this, we will perform 2 \[11C\]PBR28 PET scans. The first will quantify the total \[11C\]PBR28 PET signal. This signal is a combination of the specific signal (VS) and the nonspecific signal (VND). The second scan will be performed following dosing with an unlabelled TSPO ligand. By directly measuring the total \[11C\]PBR28 signal (scan 1) and the nonspecific \[11C\]PBR28 signal (scan 2) we can therefore calculate the specific \[11C\]PBR28 signal, and hence the amount of TSPO in the lung.

Conditions

• Pulmonary Arterial Hypertension
• Healthy

Interventions

Type	Name	Description
RADIATION	TSPO PET scan (11C-PBR28)	PET scan

Timeline

• Start date: 2023-02-01
• Primary completion: 2025-02-01
• Completion: 2025-04-01
• First posted: 2023-02-27
• Last updated: 2024-10-15

Locations

1 site across 1 country: United Kingdom